|
業務類別
|
Biotechnology |
|
業務概覽
|
NeOnc Technologies Holdings Inc. is a clinical-stage biopharmaceutical company focused on developing novel molecular technologies for the targeted delivery of therapeutics to treat central nervous system diseases. The company is developingdrug delivery methods and drug candidates for intracranial malignancies such as gliomas, glioblastoma, and meningioma. Its lead product candidates include NEO100, an intranasal drug delivery therapy for brain cancer patients, and NEO212, an oral chemical conjugate designed to enhance treatment for glioblastoma. |
| 公司地址
| 23975 Park Sorrento, Suite 205, Calabasas, CA, USA, 91302 |
| 電話號碼
| +1 310 663-7831 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.neonc.com |
| 員工數量
| 5 |
| Mr. Keithly Garnett |
Chief Financial Officer |
美元 195.00K |
31/03/2026 |
| Mr. David Choi |
Chief Accounting Officer |
-- |
17/03/2026 |
| Dr. Thomas Chen, M.D.,PhD |
Vice Chairman of the Board, Chief Medical Officer and Chief Scientific Officer |
美元 212.00K |
31/03/2026 |
| Mr. Josh Neman |
Chief Clinical Officer |
-- |
06/06/2025 |
| Mr. Amir Heshmatpour |
Executive Chairman of the Board, Chief Executive Officer, President and Secretary |
-- |
31/03/2026 |
|
|
| Dr. Sikirat Iyabo Tinubu-Karch, M.D. |
Independent Director |
01/03/2024 |
| Dr. Victoria Medvec |
Independent Director |
31/03/2026 |
| Mr. Bader Al monawer |
Independent Director |
31/03/2026 |
| Mr. Richard D. Nanula |
Independent Director |
01/03/2024 |
| The Honourable Jimmy Delshad |
Independent Director |
31/03/2026 |
| Dr. Thomas Chen, M.D.,PhD |
Vice Chairman of the Board, Chief Medical Officer and Chief Scientific Officer |
31/03/2026 |
| Dr. Steven L. Giannotta |
Independent Director |
31/03/2026 |
| Mr. Amir Heshmatpour |
Executive Chairman of the Board, Chief Executive Officer, President and Secretary |
31/03/2026 |
| Dr. Ming-Fu Chiang |
Director |
31/03/2026 |
|
|
|
|
